MCID: DXR001
MIFTS: 40

Doxorubicin Induced Cardiomyopathy

Categories: Rare diseases, Cardiovascular diseases

Aliases & Classifications for Doxorubicin Induced Cardiomyopathy

MalaCards integrated aliases for Doxorubicin Induced Cardiomyopathy:

Name: Doxorubicin Induced Cardiomyopathy 53

Classifications:



Summaries for Doxorubicin Induced Cardiomyopathy

MalaCards based summary : Doxorubicin Induced Cardiomyopathy is related to pulmonary blastoma and deafness, autosomal recessive 39. An important gene associated with Doxorubicin Induced Cardiomyopathy is GATA4 (GATA Binding Protein 4), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Doxorubicin and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include breast, heart and bone, and related phenotypes are Decreased cell migration and Decreased substrate adherent cell growth

Related Diseases for Doxorubicin Induced Cardiomyopathy

Diseases related to Doxorubicin Induced Cardiomyopathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 19)
# Related Disease Score Top Affiliating Genes
1 pulmonary blastoma 10.2 DES EGFR
2 deafness, autosomal recessive 39 10.1 HGF MET
3 deafness, autosomal recessive 97 10.1 HGF MET
4 endometrial squamous cell carcinoma 10.0 HGF MET
5 large cell medulloblastoma 10.0 HGF MET
6 sarcoma 9.9
7 wrinkles 9.8 CSF3 HGF
8 papillary thyroid microcarcinoma 9.8 HGF MET
9 insulin-like growth factor i 9.7
10 vaginitis 9.7
11 neuronitis 9.7
12 soft tissue sarcoma 9.7
13 endotheliitis 9.7
14 familial renal papillary carcinoma 9.6 EGFR HGF MET
15 chordoma 9.6 DES EGFR MET
16 spinal chordoma 9.6 EGFR HGF MET
17 ewing's family of tumors 9.6 CSF3 EPOR
18 spindle cell synovial sarcoma 9.5 HGF MET
19 anemia of prematurity 9.4 CSF3 EPOR

Graphical network of the top 20 diseases related to Doxorubicin Induced Cardiomyopathy:



Diseases related to Doxorubicin Induced Cardiomyopathy

Symptoms & Phenotypes for Doxorubicin Induced Cardiomyopathy

GenomeRNAi Phenotypes related to Doxorubicin Induced Cardiomyopathy according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased cell migration GR00055-A-1 9.56 MET EGFR EPHB2 MAPK14
2 Decreased substrate adherent cell growth GR00193-A-2 9.33 EGFR EPHB2 MAPK14
3 Decreased viability after Chlamydia trachomatis serovar L2 infection and TNF-alpha/CHX stimulation GR00206-A 8.96 MET MAPK14
4 Increased cell viability after pRB stimulation GR00230-A-1 8.8 MET EGFR MAPK14

MGI Mouse Phenotypes related to Doxorubicin Induced Cardiomyopathy:

46 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.18 GATA4 MET HGF MAPK14 DES EPHB2
2 cardiovascular system MP:0005385 10.14 GATA4 MET HGF MAPK14 DES ECE1
3 growth/size/body region MP:0005378 10.13 GATA4 MET HGF MAPK14 EPHB2 ECE1
4 embryo MP:0005380 10.04 GATA4 MET HGF MAPK14 ECE1 EPOR
5 homeostasis/metabolism MP:0005376 10.03 MAPK14 GATA4 MET EGFR DES ECE1
6 mortality/aging MP:0010768 10.02 MET HGF MAPK14 GATA4 DES EPHB2
7 hematopoietic system MP:0005397 10 MAPK14 GATA4 HGF EPOR CSF3 EGFR
8 digestive/alimentary MP:0005381 9.99 GATA4 MET EPHB2 ECE1 CNR1 EGFR
9 integument MP:0010771 9.88 MAPK14 GATA4 CSF3 EGFR ECE1 CNR1
10 liver/biliary system MP:0005370 9.85 GATA4 MET HGF MAPK14 EPOR EGFR
11 nervous system MP:0003631 9.76 MAPK14 GATA4 MET EGFR EPHB2 ECE1
12 muscle MP:0005369 9.73 MAPK14 GATA4 MET DES ECE1 EGFR
13 no phenotypic analysis MP:0003012 9.43 GATA4 MET HGF EPOR CNR1 EGFR
14 normal MP:0002873 9.17 GATA4 MET MAPK14 ECE1 EPOR CNR1

Drugs & Therapeutics for Doxorubicin Induced Cardiomyopathy

Drugs for Doxorubicin Induced Cardiomyopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 11)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 2,Not Applicable 23214-92-8 31703
2
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
3
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
4
Doxil Approved June 1999 Phase 2,Not Applicable 31703
5 Topoisomerase Inhibitors Phase 2,Not Applicable
6 Anti-Bacterial Agents Phase 2,Not Applicable
7 Antibiotics, Antitubercular Phase 2,Not Applicable
8 Albumin-Bound Paclitaxel Phase 2
9
Menthol Approved Not Applicable 2216-51-5 16666
10 Chelating Agents Not Applicable
11 Gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate Not Applicable

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 99mTc-rhAnnexin V-128 Imaging and Cardiotoxicity in Patients With Early Breast Cancer Recruiting NCT02677714 Phase 2
2 Correlation Between Genetic Variants and Long-term Cardiac Effects Induced by Doxorubicin in Breast Cancer Patients Unknown status NCT02078388 Doxorubicin
3 Prevention Using Exercise Rehabilitation to Offset Cardiac Toxicities Induced Via Chemotherapy Unknown status NCT02796365 Not Applicable
4 Doxorubicin-associated Cardiac Remodeling Followed by CMR in Breast Cancer Patients Completed NCT03000036 Not Applicable Doxorubicin;Gadoterate Meglumine
5 The Role of suPAR Biomarker in Blood Samples of Breast Cancer Patients During and Post Doxorubicin Chemotherapy: Causative vs. Predictor Recruiting NCT03505164

Search NIH Clinical Center for Doxorubicin Induced Cardiomyopathy

Genetic Tests for Doxorubicin Induced Cardiomyopathy

Anatomical Context for Doxorubicin Induced Cardiomyopathy

MalaCards organs/tissues related to Doxorubicin Induced Cardiomyopathy:

41
Breast, Heart, Bone, Bone Marrow, Pituitary, Endothelial, Testes

Publications for Doxorubicin Induced Cardiomyopathy

Articles related to Doxorubicin Induced Cardiomyopathy:

(show top 50) (show all 148)
# Title Authors Year
1
Anti-oxidant effect of bergamot polyphenolic fraction counteracts doxorubicin-induced cardiomyopathy: Role of autophagy and c-kit<sup>pos</sup>CD45<sup>neg</sup>CD31<sup>neg</sup> cardiac stem cell activation. ( 29654879 )
2018
2
Ability of Nonstrain Diastolic Parameters to Predict Doxorubicin-Induced Cardiomyopathy: A Systematic Review With Meta-Analysis. ( 29045286 )
2018
3
Cardiac progenitor cells activated by mitochondrial delivery of resveratrol enhance the survival of a doxorubicin-induced cardiomyopathy mouse model via the mitochondrial activation of a damaged myocardium. ( 29146241 )
2018
4
Molecular mechanism of doxorubicin-induced cardiomyopathy - An update. ( 29074412 )
2018
5
A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish. ( 29939187 )
2018
6
Embryonic stem cell-derived cardiomyocytes for the treatment of doxorubicin-induced cardiomyopathy. ( 29402309 )
2018
7
Localized Doxorubicin-Induced Cardiomyopathy Complicated With Shower Emboli Originating From Apical Intramural Thrombi. ( 29459534 )
2018
8
Expression of Flk-1 and Cyclin D2 mRNA in the Myocardium of Rats with Doxorubicin-Induced Cardiomyopathy and after Treatment with Betulonic Acid Amide. ( 29063324 )
2017
9
Short-term and long-term models of doxorubicin-induced cardiomyopathy in rats: A comparison of functional and histopathological changes. ( 28153388 )
2017
10
Mechanistic clues to the protective effect of chrysin against doxorubicin-induced cardiomyopathy: Plausible roles of p53, MAPK and AKT pathways. ( 28684738 )
2017
11
Prevention of doxorubicin-induced cardiomyopathy using targeted MaFGF mediated by nanoparticles combined with ultrasound-targeted MB destruction. ( 29026304 )
2017
12
Early transcriptional alteration of histone deacetylases in a murine model of doxorubicin-induced cardiomyopathy. ( 28662206 )
2017
13
Angiotensin-converting enzyme 2 overexpression protects against doxorubicin-induced cardiomyopathy by multiple mechanisms in rats. ( 28445944 )
2017
14
Correction to: &amp;quot;Early Administration of Carvedilol Protected against Doxorubicin-Induced Cardiomyopathy.&amp;quot; ( 28087848 )
2017
15
Folic acid reduces doxorubicin-induced cardiomyopathy by modulating endothelial nitric oxide synthase. ( 28608983 )
2017
16
Honokiol, an activator of Sirtuin-3 (SIRT3) preserves mitochondria and protects the heart from doxorubicin-induced cardiomyopathy in mice. ( 28423723 )
2017
17
Vitamin C mitigates oxidative/nitrosative stress and inflammation in Doxorubicin-induced cardiomyopathy. ( 28710069 )
2017
18
Sirt3 protects mitochondrial DNA damage and blocks the development of doxorubicin-induced cardiomyopathy in mice. ( 26873966 )
2016
19
Matricellular protein CCN1 mediates doxorubicin-induced cardiomyopathy in mice. ( 27167338 )
2016
20
Sarco&amp;quot;MiR&amp;quot; friend or foe: a perspective on the mechanisms of doxorubicin-induced cardiomyopathy. ( 27294099 )
2016
21
Protective effect of Co-enzyme Q10 On doxorubicin-induced cardiomyopathy of rat hearts. ( 27087047 )
2016
22
Obestatin attenuated doxorubicin-induced cardiomyopathy via enhancing long noncoding Mhrt RNA expression. ( 27261628 )
2016
23
Early Administration of Carvedilol Protected against Doxorubicin-Induced Cardiomyopathy. ( 26511374 )
2015
24
A metabolomic study of rats with doxorubicin-induced cardiomyopathy and Shengmai injection treatment. ( 25938766 )
2015
25
Astragalus polysaccharide improves cardiac function in doxorubicin-induced cardiomyopathy through ROS-p38 signaling. ( 26885153 )
2015
26
Protective effects of endothelin receptor A and B inhibitors against doxorubicin-induced cardiomyopathy. ( 25660617 )
2015
27
Yogurt Containing the Probacteria Lactobacillus acidophilus Combined with Natural Antioxidants Mitigates Doxorubicin-Induced Cardiomyopathy in Rats. ( 25590792 )
2015
28
Protective effect of cilostazol against doxorubicin-induced cardiomyopathy in mice. ( 26191652 )
2015
29
Heart rate dynamics in doxorubicin-induced cardiomyopathy. ( 25798626 )
2015
30
Shengmai injection improved Doxorubicin-induced cardiomyopathy by alleviating myocardial endoplasmic reticulum stress and caspase-12 dependent apoptosis. ( 25839043 )
2015
31
Cannabidiol protects against doxorubicin-induced cardiomyopathy by modulating mitochondrial function and biogenesis. ( 25569804 )
2015
32
Potent Paracrine Effects of human induced Pluripotent Stem Cell-derived Mesenchymal Stem Cells Attenuate Doxorubicin-induced Cardiomyopathy. ( 26057572 )
2015
33
Cyclovirobuxine D Attenuates Doxorubicin-Induced Cardiomyopathy by Suppression of Oxidative Damage and Mitochondrial Biogenesis Impairment. ( 26075032 )
2015
34
Visnagin protects against doxorubicin-induced cardiomyopathy through modulation of mitochondrial malate dehydrogenase. ( 25504881 )
2014
35
Embryonic Stem Cells and Released Factors Stimulate c-kit (+ve) /FLK-1(+ve) Progenitor Cells and Promote Neovascularization in Doxorubicin-induced Cardiomyopathy. ( 24593859 )
2014
36
Arginase inhibition augments nitric oxide production and facilitates left ventricular systolic function in doxorubicin-induced cardiomyopathy in mice. ( 25263201 )
2014
37
Cardioprotective effect of ammonium glycyrrhizinate against doxorubicin-induced cardiomyopathy in experimental animals. ( 25298583 )
2014
38
Oleuropein prevents doxorubicin-induced cardiomyopathy interfering with signaling molecules and cardiomyocyte metabolism. ( 24486195 )
2014
39
Therapeutic use of H2O2-responsive anti-oxidant polymer nanoparticles for doxorubicin-induced cardiomyopathy. ( 24767791 )
2014
40
Manipulation of Cardiac PI3K/Akt Signaling by Apoptosis regulator through modulating IAP expression (ARIA) Regulates Cardiomyocyte Death during the Doxorubicin-induced Cardiomyopathy. ( 24338479 )
2013
41
Increased beta2-adrenoceptors in doxorubicin-induced cardiomyopathy in rat. ( 23741376 )
2013
42
Macrophage migration inhibitory factor deficiency augments doxorubicin-induced cardiomyopathy. ( 24334905 )
2013
43
Interrelation between Expression of ADAM 10 and MMP 9 and Synthesis of Peroxynitrite in Doxorubicin Induced Cardiomyopathy. ( 24244825 )
2013
44
The beneficial effects of tadalafil on left ventricular dysfunction in doxorubicin-induced cardiomyopathy. ( 23731918 )
2013
45
Effects of Histidine and N-Acetylcysteine on Doxorubicin-Induced Cardiomyopathy in Rats. ( 24343415 )
2013
46
Antioxidant, lipid lowering, and membrane stabilization effect of sesamol against doxorubicin-induced cardiomyopathy in experimental rats. ( 24228260 )
2013
47
Doxorubicin-induced cardiomyopathy 17 years after chemotherapy. ( 22719160 )
2012
48
Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. ( 22465037 )
2012
49
Effects of the antioxidant agent tempol on periapical lesions in rats with doxorubicin-induced cardiomyopathy. ( 22244634 )
2012
50
Toll-like receptor (TLR) 2 and TLR4 differentially regulate doxorubicin induced cardiomyopathy in mice. ( 22808256 )
2012

Variations for Doxorubicin Induced Cardiomyopathy

Expression for Doxorubicin Induced Cardiomyopathy

Search GEO for disease gene expression data for Doxorubicin Induced Cardiomyopathy.

Pathways for Doxorubicin Induced Cardiomyopathy

Pathways related to Doxorubicin Induced Cardiomyopathy according to GeneCards Suite gene sharing:

(show all 33)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.58 CSF3 DES EGFR EPHB2 EPOR HGF
2
Show member pathways
13.49 EGFR EPHB2 EPOR GATA4 HGF MAPK14
3
Show member pathways
13.35 EGFR EPHB2 EPOR HGF MAPK14 MET
4
Show member pathways
13.27 EGFR EPHB2 EPOR HGF MAPK14 MET
5
Show member pathways
13.2 CSF3 ECE1 EGFR EPHB2 EPOR HGF
6
Show member pathways
13.13 EGFR EPHB2 EPOR HGF MET
7
Show member pathways
13.02 EGFR EPHB2 EPOR HGF MAPK14 MET
8
Show member pathways
12.85 CSF3 EGFR EPHB2 EPOR HGF MAPK14
9
Show member pathways
12.83 EGFR EPHB2 HGF MAPK14 MET
10
Show member pathways
12.75 CSF3 EGFR EPOR HGF MET
11
Show member pathways
12.72 EGFR HGF MAPK14 MET
12
Show member pathways
12.71 EGFR EPHB2 EPOR MAPK14 MET
13
Show member pathways
12.68 EGFR EPOR GATA4 MAPK14
14 12.65 EGFR EPOR HGF MET
15
Show member pathways
12.59 EGFR HGF MAPK14 MET
16 12.58 EGFR HGF MAPK14 MET
17
Show member pathways
12.41 CNR1 EGFR HGF MAPK14 MET
18
Show member pathways
12.18 HGF MAPK14 MET
19 12.06 EGFR HGF MAPK14 MET
20 11.95 EGFR EPHB2 MET
21 11.89 GATA4 HGF MET
22 11.88 EGFR HGF MET
23
Show member pathways
11.88 EGFR HGF MAPK14 MET
24
Show member pathways
11.68 EGFR HGF MET
25 11.3 CSF3 HGF MET
26
Show member pathways
11.2 EGFR HGF MET
27 11.14 EGFR MET
28 11.1 EGFR HGF MET
29 11.07 EGFR EPOR
30 11.03 GATA4 MAPK14
31 10.83 HGF MET
32 10.66 EGFR HGF MET
33 10.28 EGFR HGF MET

GO Terms for Doxorubicin Induced Cardiomyopathy

Cellular components related to Doxorubicin Induced Cardiomyopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.17 CSF3 EGFR EPHB2 EPOR HGF MAPK14
2 basal plasma membrane GO:0009925 9.16 EGFR MET
3 receptor complex GO:0043235 9.13 EGFR EPHB2 MET

Biological processes related to Doxorubicin Induced Cardiomyopathy according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 protein phosphorylation GO:0006468 9.88 EGFR EPHB2 MAPK14 MET
2 positive regulation of transcription by RNA polymerase II GO:0045944 9.88 CSF3 EGFR GATA4 HGF MAPK14 MET
3 negative regulation of apoptotic process GO:0043066 9.87 EGFR EPHB2 HGF MET
4 heart development GO:0007507 9.77 ECE1 EPOR GATA4
5 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.77 EGFR EPHB2 MET
6 MAPK cascade GO:0000165 9.76 EGFR HGF MAPK14 MET
7 positive regulation of MAPK cascade GO:0043410 9.73 EGFR EPHB2 MET
8 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.71 EGFR EPHB2 MET
9 negative regulation of signal transduction GO:0009968 9.7 EGFR EPHB2 MET
10 phosphatidylinositol phosphorylation GO:0046854 9.67 EGFR HGF MET
11 liver development GO:0001889 9.65 EGFR HGF MET
12 positive regulation of kinase activity GO:0033674 9.61 EGFR EPHB2 MET
13 positive chemotaxis GO:0050918 9.58 HGF MET
14 axonal fasciculation GO:0007413 9.55 CNR1 EPHB2
15 learning or memory GO:0007611 9.54 CNR1 EGFR EPHB2
16 hepatocyte growth factor receptor signaling pathway GO:0048012 9.51 HGF MET
17 peptidyl-tyrosine phosphorylation GO:0018108 9.46 EGFR EPHB2 HGF MET
18 negative regulation of autophagy GO:0010507 9.43 GATA4 HGF MET
19 negative regulation of hydrogen peroxide-mediated programmed cell death GO:1901299 9.32 HGF MET
20 positive regulation of protein kinase B signaling GO:0051897 9.26 CSF3 EGFR HGF MET
21 cell morphogenesis GO:0000902 8.92 EGFR EPHB2 HGF MAPK14

Molecular functions related to Doxorubicin Induced Cardiomyopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase activity GO:0004672 9.78 EGFR EPHB2 MAPK14 MET
2 identical protein binding GO:0042802 9.73 DES EGFR EPHB2 EPOR HGF MET
3 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.63 EGFR HGF MET
4 MAP kinase kinase kinase activity GO:0004709 9.61 EGFR EPHB2 MET
5 protein phosphatase binding GO:0019903 9.58 EGFR MAPK14 MET
6 mitogen-activated protein kinase kinase binding GO:0031434 9.54 EGFR EPHB2 MET
7 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.5 EGFR HGF MET
8 NFAT protein binding GO:0051525 9.16 GATA4 MAPK14
9 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.13 EGFR EPHB2 MET
10 protein tyrosine kinase activity GO:0004713 8.92 EGFR EPHB2 HGF MET

Sources for Doxorubicin Induced Cardiomyopathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....